TVRD
Tvardi Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
TVRD Profile
Tvardi Therapeutics, Inc.
A clinical stage biopharmaceutical company specializing in the development of small molecule inhibitors targeting STAT3
3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas
--
Tvardi Therapeutics, Inc., incorporated on December 20, 2017, is a Delaware corporation headquartered in Houston, Texas. The Company is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies for STAT3 to treat fibrosis-driven diseases with significant unmet needs. Based on the pioneering work of its founders and a deep understanding of the transcription factor STAT3, the company has devised an innovative method to directly inhibit STAT3, a highly proven but historically non-drugable target. Using this expertise, the company is developing a pipeline of STAT3 inhibitors with differentiated mechanisms of action and convenient oral administration. The company's lead product candidate, TTI-101, is currently in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis, IPF and hepatocellular carcinoma, HCC.